Sartorius AG (Sartorius AG) ROCE % : 6.30% (As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Sartorius AG ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Sartorius AG's annualized ROCE % for the quarter that ended in Mar. 2024 was 6.30%.

Sartorius AG ROCE % Historical Data

The historical data trend for Sartorius AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sartorius AG ROCE % Chart

Sartorius AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

14.83

15.88

17.30

25.35

7.89

Sartorius AG Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															15.20	15.54	4.53	3.17	6.30

Sartorius AG ROCE % Calculation

Sartorius AG's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	578.844	/	( ( (7391.631 - 1910.275)	+	(10638.277 - 1450.164) )	/ 2 )
	=	578.844	/	( (5481.356	+	9188.113)	/ 2 )
	=	578.844	/	7334.7345
	=	7.89 %

Sartorius AG's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	606.52	/	( ( (10638.277 - 1450.164)	+	(11551.957 - 1492.174) )	/ 2 )
	=	606.52	/	( ( 9188.113	+	10059.783 )	/ 2 )
	=	606.52	/	9623.948
	=	6.30 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Sartorius AG (OTCPK:SARTF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Sartorius AG ROCE % Related Terms

Thank you for viewing the detailed overview of Sartorius AG's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sartorius AG (Sartorius AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sartorius AG (OTCPK:SARTF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

SOAGY:USA SSSGY:USA SUVPF:USA 1SRT3:Italy SRT3d:UK 0NIR:UK SRT3:Germany SRT3:Austria

Address

Otto-Brenner-Strasse 20, Gottingen, NI, DEU, 37079

Website

https://www.sartorius.com

Sartorius AG is a leading provider of bioprocessing solutions. Its Bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology, or SUT. Its Lab Products and Services division offers a wide range of products for lab use, including scales, pipettes, and filtration equipment. As of 2022, the Bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 74% ownership and 85% voting control. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (37% of 2022 sales), the Americas (37%), and Asia-Pacific (26%). We estimate China revenue to be around 10%.